A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Mitomycin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OLYMPUS
- Sponsors UroGen Pharma
- 27 Nov 2017 According to a UroGen Pharma media release, design overview of this trial will be presented at the 18th annual meeting of the Society of Urologic Oncology (SUO),
- 22 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Aug 2019.
- 22 Nov 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2018.